- Home
- ASA vs RVNC Comparison
ASA vs RVNC Comparison
Compare ASA & RVNC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ASA
- RVNC
- Stock Information
- Founded
- ASA 1958
- RVNC 1999
- Country
- ASA United States
- RVNC United States
- Employees
- ASA N/A
- RVNC N/A
- Industry
- ASA Precious Metals
- RVNC Biotechnology: Pharmaceutical Preparations
- Sector
- ASA Industrials
- RVNC Health Care
- Exchange
- ASA Nasdaq
- RVNC Nasdaq
- Market Cap
- ASA 393.9M
- RVNC 320.5M
- IPO Year
- ASA N/A
- RVNC 2014
- Fundamental
- Price
- ASA $20.04
- RVNC $3.09
- Analyst Decision
- ASA
- RVNC Hold
- Analyst Count
- ASA 0
- RVNC 9
- Target Price
- ASA N/A
- RVNC $8.45
- AVG Volume (30 Days)
- ASA 54.3K
- RVNC 3.6M
- Earning Date
- ASA 01-27-2025
- RVNC 11-07-2024
- Dividend Yield
- ASA 0.20%
- RVNC N/A
- EPS Growth
- ASA 302.95
- RVNC N/A
- EPS
- ASA 4.56
- RVNC N/A
- Revenue
- ASA $1,993,559.00
- RVNC $256,945,000.00
- Revenue This Year
- ASA N/A
- RVNC $11.28
- Revenue Next Year
- ASA N/A
- RVNC $27.21
- P/E Ratio
- ASA $4.38
- RVNC N/A
- Revenue Growth
- ASA N/A
- RVNC 25.82
- 52 Week Low
- ASA $13.18
- RVNC $2.30
- 52 Week High
- ASA $22.78
- RVNC $9.75
- Technical
- Relative Strength Index (RSI)
- ASA 44.99
- RVNC 33.47
- Support Level
- ASA $19.37
- RVNC $3.06
- Resistance Level
- ASA $20.44
- RVNC $3.09
- Average True Range (ATR)
- ASA 0.58
- RVNC 0.11
- MACD
- ASA -0.08
- RVNC 0.02
- Stochastic Oscillator
- ASA 25.97
- RVNC 6.90
About ASA ASA Gold and Precious Metals Limited
ASA Gold And Precious Metals Ltd is a closed-end, non-diversified investment company. Its objective is to provide long-term capital appreciation through investing in companies engaged in the exploration for, development of projects, or mining of precious metals and minerals.
About RVNC Revance Therapeutics Inc.
Revance Therapeutics Inc is a biotechnology company focused on aesthetic and therapeutic offerings, including its neuromodulator product, DaxibotulinumtoxinA for Injection. The company has launched a prestige aesthetics portfolio, which includes the RHA Collection of dermal fillers and the HintMD platform. Its main products include DaxibotulinumtoxinA for Injection and DaxibotulinumtoxinA for Injection Aesthetics. The operating business segments are the Product and the Service Segment. The Products segment generates maximum revenue and is engaged in the research and development of aesthetic and therapeutic products.